We are pleased to announce that results from Alnylam’s preclinical research into novel #siRNA delivery technology, including proof-of-concept findings in #AlzheimersDisease, have been published in Nature Biotechnology. #RNAi #RNAitherapeutics

Getting Recharged! Water feels like ‘amruta’ after 7-mile hike around Jenny lake in the backdrop of Grand Teton.

Our poster at the OTS. So cool to see this new application of RNAi for dynamic control of AAV gene expression. Top notch research project led by Megha. More at: biorxiv.org/content/10.110…

The October issue is live nature.com/nbt/volumes/40… On our cover, 2′-𝘖-hexadecyl (C16)-conjugated siRNA in complex with RISC and mRNA. C16-conjugated siRNA achieves efficient, durable targeted gene silencing in the central nervous system, eye and lung go.nature.com/3aEbgQH

Sun shining on the Genetown! From Blue hills this morning

100 years after his birth, Kurt Vonnegut is more relevant than ever to science science.org/content/articl…

Wonderful to spend time with Vasant Jadhav, ⁦Alnylam Pharmaceuticals⁩ platform chief, this am! The kainotomia is boundless!

Life imitates trials it seems. Our early experience of use of inclisiran in our hospital in London. openheart.bmj.com/content/openhr…

So pleased to report this new application of RNAi as molecular switch for AAV transgene expression. Elegant demonstration of the concept with so many moving parts working well together. This paper continues the tradition of quality publications from Alnylam over last 20 years.

Continues to look impressive! Go Leqvio and GalNAc-siRNA Platform! Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years novartis.com/news/media-rel…

Wonderful to see this work published showing human translation of ESC+ design. From concept to clinic. journal-of-hepatology.eu/article/S0168-…

What a fantastic Nature meeting with unique agenda- optional *FREE* CAREER DAY and who’s who of RNA World speakers! conferences.nature.com/ZLONmr?sms=2

Akshay reflecting on Alnylam resilience in fireside chat with Jason Rhodes at the Atlas Retreat.

Evaluating the oral delivery of GalNAc-conjugated siRNAs in rodents and non-human primates academic.oup.com/nar/article/do…

We are pleased to share positive topline results from our HELIOS-B Phase 3 study of vutrisiran, an investigational #RNAi therapeutic in development for the treatment of #ATTR #amyloidosis w/ cardiomyopathy. Read the press release: bit.ly/3VwvRtY #RNAiTherapeutics #siRNA

Bros of Alnylam R&D- Pushkal, Kevin, Akshay

Developers use operating systems like iOS or Android to quickly and easily create new apps. We use our #RNAiTherapeutics platform similarly to quickly develop investigational medicines. A new Nature Portfolio article (sponsored content; for US audiences only) explains how. #RNAi

Great insights from Bruce and Atlas team.

26 years after arriving in US. The baggage tag is still there showing multiple halts of the long journey. It has been a great ride since arriving in Beautiful Boulder to now in Boston Strong.

High resistance barrier and prophylactic protection in preclinical models of SARS-CoV-2 with two siRNA combination academic.oup.com/nar/article/do…